# Supplementary information

# **Supplementary Tables**

Table S1. The qRT-PCR primer sequences for mRNA

expression

Primer	2001102000		
name	sequences		
AR	F: 5'-TgTCCATCTTgTCgTCTTC-3'		
	R: 5'-CCTCTCCTTCCTCCTgTAg-3'		
AhR	F: 5'-CCACTTCAgCCACCATCCAT-3'		
	R: 5'-AAgCAggCgTgCATTAgACT-3'		
ABCG2	F: 5'-gggTTCTCTTCTTCCTgACgACC-3'		
	R: 5'-TggTTgTgA gATTgACCAACAgACC-3'		

Primer name	location	sequences	
Full length	-3268/+362	F:5'gAgCTCgCAgCCTTgAACCCCgggggCTCAAgC3' R:5'gggAAgCTTgCACggTgCgTTCCTAAATCCTACCC3'	
1F1R	-3268/-1396	F:5'gAgCTCgCAgCCTTgAACCCCgggggCTCAAgC3' R:5'gggAAgCTTggCCgTTAATgACTgTTTgCAAAAACT3'	
2F4R	-1396/+362	F:5'gAgCTCAgTTTTTgCAAACAgTCATTAACggCC3' R:5'gggAAgCTTgCACggTgCgTTCCTAAATCCTACCC3'	
3F4R	-959/+362	F:5'gAgCTCAATTTTACCCAAATgTTTgggCgCA3' R:5'gggAAgCTTgCACggTgCgTTCCTAAATCCTACCC3'	
4F4R	-523/+362	F:5'gAgCTCTTCATTCAgTAAgTTTCTCCCCTTTCC3' R:5'gggAAgCTTgCACggTgCgTTCCTAAATCCTACCC3'	

 Table S2. The PCR primers sequencing for ABCG2 promoter region amplification

Table S3. The qRT-PCR primer sequences for ChIP

assay		
Primer	sequences	
name		
ChIPR1.2F	F: 5'-gACTTggAACCAACCCAAATg-3'	
ChIPR1.2R	R: 5'-TCCCTACAAAggACATgAACTC-3'	
ChIPR2.5F	F: 5'-ggCCTTTAAgggTCTTgAAACTg-3'	
ChIPR2.5R	R: 5'-TggTTCACCCAATgCAggAAA-3'	
ChIPR3.4F	F: 5'-gCCTTTCCACACCATCggA-3'	
ChIPR3.4R	R: 5'-AggAAAggggAgAAACTTACTg-3'	

Cell line	Manipulation	IC <sub>50</sub>
	Vector control	0.0059 ±0.004 µM*
Hey A8	hAR	0.024 ±0.019 μM*
	siAR	0.0011 ±0.0002 μM
SKOV3ip1	Vector control	0.003 ±0.002 μM*
	hAR	0.008 ±0.001 µM*
	siAR	0.0025 ±0.002 μM
OVCAR3	Vector control	0.001 µM*
	hAR	0.009 ±0.002 μM*
	siAR	0.001 µM


**Table S4.**  $IC_{50}$  of AR-manipulated EOC cells under paclitaxel<br/>treatment (\* p < 0.05)</th>

Cell line	treatments	IC <sub>50</sub>
Hey A8	Paclitaxel	0.0063 ± 0.003 μM
	Paclitaxel/ 10 µM MDV	0.0051 ± 0.0028 μM
	Paclitaxel/ 5 µM ASC-J9	0.0016 ± 0.0005 μM
	Paclitaxel	$0.0058 \pm 0.0007 \ \mu M$
SKOV3ip1	Paclitaxel/ 10 µM MDV	0.0054 ± 0.0005 μM
	Paclitaxel/ 5 µM ASC-J9	0.002 ± 0.001 μM
	Paclitaxel	0.002 ± 0.001 μM
OVCAR3	Paclitaxel/ 10 µM MDV	0.0027 ± 0.0003 μM
	Paclitaxel/ 5 µM ASC-J9	0.0007 ± 0.00026 μM

 Table S5. IC<sub>50</sub> of EOC cells treated by paclitaxel combined with ASC-J9 or MDV3100

### **Supplementary figures**

### Supplementary Figure S1. Chung et al



Supplementary Figure S1. AR expression and association with paclitaxel sensitivity and resistance. (A) Basal expression of AR mRNA in three serous type cells. Actin was used as an internal control. (B) Overexpression of AR in three EOC serous subtype cell lines. Cells were infected with either pWPI vector control or pWPI-hAR plasmids to establish AR-stable clones. Cells with AR overexpression were then lysed to perform western blotting. Total protein was loaded at 40µg/lane and AR antibody was used to detect AR expression. Actin was used as an internal control. (C) Cells were infected with either pLKO.1-shLuc vector control or pLKO.1-shAR plasmids to establish AR-knockdown stable clones. Knockdown of AR expression in EOC serous subtype cells. RNA was extracted and cDNA was synthesized using 5µg of total RNA. AR expression was determined using qRT-PCR. Actin was used as an internal control. Results of mRNA expression were calculated by  $2^{-\Delta\Delta Ct}$  and normalized by shLuc.


#### Supplementary Figure S2, Chung et al.

a at control a control of the state of th ggtgtggcgattcctcagggatctagaactagaaataccatttgacccagccatcccattactgggtatatacccaaaggactataaatcatgctgctataaagacacatgcacacgtatgtttattgcagagatagggtctcagtatgttgcccaggtggtcttgaactcctgggctcaagcaattctttggcctctgccccaaagtgttgggattacaggagtgagctgtcactccttgccccagcaattttctacglalaggititititititititititititititigagalggagtctcacgtgtcaccaggctagagggcggaggagtagatcttggctcacgcactctgcctcccggctccagcattctcctgcctcagcattctcctgcctcagcattctcctgctccagcattctcctgctccagcattctcctgctccagcattctcctgctccagcattctcctgctccagcattctcctgctccagcattctcctgctccagcattctcctgctccagcattctcctgctccagcattctcctgctccagcattctcctgctccagcattctccagcattctccagcattctagcattctcagcattctcagcattctcagcattctcagcattctcagcattctcagcattctcagcattctcagcattctcagcattctcagcattctcagcattctcagcattctcagcattctcagcattctcagcattctagcattctcagcattctcagcattctcagcattc cctgggtagctgggattacaggcatgagccaccatgcccggctaatttttgtattttagtagagaagggtttcaccatgttggccaggctgctcttgaagtcctgatatcaggtgatccacctgcctcgcct ccca a a tacta ca tacta ca tacta ca tacta ca tacta ca ta ta tacta ca tacaaattaaaataaaatttatttitteggagattttteagttittgeaaaegteattaaeggeeaggtetgaaaaetttatettaatttitttittittittettgagaeaggeteegtetgaggeeggagtgcagtggtgggatctcgggtcatttgcaacctctgcctcctgtgttcaagcgcttcttgttccttagcctcgcgagtagctgggattacagcctcgccaccacccagctaacttttgtattttagtagaaagcatgcggtatggtatatttaaaattotttttaaaaattatgtatagtcaatttottatctaggcttoctagctaaaactttoctgcattgggtgaaccattaatagttattoctagtgttgatttaacaae ARE re DRE gcaggacacglglgcgctltcagccggglcgcagggcgctlatcgcggccccggcaglcggggccacgcctcaccccgcccgcgaaccccgacclggggaaacccgggggcgclggggagggg cactgogttoagototggoggtocacagocogaagogoggottaggaagttogtgtoagogotgootgaotogtoocotggatgtocogggtotococagogggocaccogooggotocoatogt ggttaagaccgagctctattaag

Supplementary Figure S2. Nucleotide sequences of the 5' flanking promoter region of the human ABCG2 gene. ABCG2 promoter region nucleotide sequences were obtained from NCBI database (accession no. NC\_018915). Transcription start site was indicted as +1.

## Supplementary Figure S3, Chung et al.





**Supplementary Figure S3. Luciferase activity of the human ABCG2 5'-promoters. (A)** 4F4R luciferase activity cannot be induced under TCDD or DHT treatment in EOC cells. Upper panel: 4F4R and pRL-TK were co-transfected into three serous type cells and treated

with DMSO,  $10^{-8}$  M DHT, or 5nM TCDD. The core DRE region is indicated as  $\Box$ . Results were the fold changes in response to DMSO treatment. Down panel: 4xDRE-luc plasmid under the same treatments served as a positive control. **(B)** 1F1R luciferase activity cannot be induced under TCDD or DHT treatment in EOC cells. 1F1R and pRL-TK were co-transfected into three serous type cells and treated with DMSO,  $10^{-8}$  M DHT, or 5nM TCDD. The putative ARE is indicated as  $\triangleright$ . Results were the fold changes in response to DMSO treatments. **(C)** 1F1R luciferase activity cannot be induced under TCDD or paclitaxel treatment in EOC cells. 1F1R and pRL-TK were co-transfected into three serous type cells. Negative control to the putative ARE is indicated as  $\triangleright$ . Results were the fold changes in response to DMSO treatments. **(C)** 1F1R luciferase activity cannot be induced under TCDD or paclitaxel treatment in EOC cells. 1F1R and pRL-TK were co-transfected into three serous type cells and treated with DMSO, 2nM paclitaxel, or 5nM TCDD.